{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T16:32:24Z","timestamp":1785256344507,"version":"3.55.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007613","name":"Ankara Universitesi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007613","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004410","name":"Scientific and Technological Research Council of Turkey","doi-asserted-by":"publisher","award":["3160858"],"award-info":[{"award-number":["3160858"]}],"id":[{"id":"10.13039\/501100004410","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jpba.2026.117554","type":"journal-article","created":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:01:55Z","timestamp":1778284915000},"page":"117554","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Comprehensive impurity profiling and stability assessment of indacaterol maleate integrating LC\u2013MS and in silico genotoxicity"],"prefix":"10.1016","volume":"278","author":[{"given":"\u00c7a\u011fla","family":"Ayd\u0131n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4886-4858","authenticated-orcid":false,"given":"Y\u00fccel","family":"Yazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halil","family":"Y\u0131lmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esen","family":"Bellur Atici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7494-3077","authenticated-orcid":false,"given":"Sibel Ay\u015f\u0131l","family":"\u00d6zkan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jpba.2026.117554_bib1","doi-asserted-by":"crossref","DOI":"10.1183\/20734735.0267-2022","article-title":"Current and future developments in the pharmacology of asthma and COPD: ERS seminar, Naples 2022","volume":"19","author":"Stolz","year":"2023","journal-title":"Breathe"},{"key":"10.1016\/j.jpba.2026.117554_bib2","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1517\/13543784.14.7.775","article-title":"Ultra long-acting \u03b22-agonists in development for asthma and chronic obstructive pulmonary disease","volume":"14","author":"Cazzola","year":"2005","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"6","key":"10.1016\/j.jpba.2026.117554_bib3","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.pupt.2006.09.001","article-title":"Safety, tolerability and efficacy of indacaterol, a novel once-daily \u03b22-agonist, in patients with COPD: A 28-day randomised, placebo controlled clinical trial","volume":"20","author":"Beier","year":"2007","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.jpba.2026.117554_bib4","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMp1109621","article-title":"The risks and benefits of indacaterol-the FDA\u2019s review","volume":"365","author":"Chowdhury","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jpba.2026.117554_bib5","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.rmed.2017.05.010","article-title":"Efficacy and safety of indacaterol in patients with chronic obstructive pulmonary disease aged over 65 years: a pooled analysis","volume":"128","author":"Girodet","year":"2017","journal-title":"Respir. Med."},{"key":"10.1016\/j.jpba.2026.117554_bib6","doi-asserted-by":"crossref","first-page":"3675","DOI":"10.1021\/jm100068m","article-title":"The identification of indacaterol as an ultralong-acting inhaled \u03b22-adrenoceptor agonist","volume":"53","author":"Baur","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jpba.2026.117554_bib7","doi-asserted-by":"crossref","first-page":"6280","DOI":"10.1016\/j.bmcl.2012.07.096","article-title":"An investigation into the structure-activity relationships associated with the systematic modification of the \u03b22-adrenoceptor agonist indacaterol","volume":"22","author":"Beattie","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.jpba.2026.117554_bib8","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1124\/dmd.112.046151","article-title":"Metabolism and Pharmacokinetics of Indacaterol in Humans","volume":"40","author":"Kagan","year":"2012","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.jpba.2026.117554_bib9","first-page":"1","article-title":"Validation of an on-line solid-phase extraction method coupled to liquid chromatography-tandem mass spectrometry detection for the determination of indacaterol in human serum","author":"Emotte","year":"2012","journal-title":"J. Chromatogr. B 895896"},{"key":"10.1016\/j.jpba.2026.117554_bib10","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.jfda.2017.08.002","article-title":"A validated capillary electrophoretic method for the determination of indacaterol and its application to a pharmaceutical preparation","volume":"26","author":"G\u00fcray","year":"2018","journal-title":"J. Food Drug Anal."},{"key":"10.1016\/j.jpba.2026.117554_bib11","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s13738-019-01778-0","article-title":"TiO2 nanoparticles and ionic liquid platform for selective electrochemical determination of indacaterol in pharmaceutical formulations and human fluids: Application to content uniformity","volume":"17","author":"Atty","year":"2020","journal-title":"J. Iran. Chem. Soc."},{"key":"10.1016\/j.jpba.2026.117554_bib12","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.saa.2016.01.002","article-title":"Simultaneous spectrophotometric determination of indacaterol and glycopyrronium in a newly approved pharmaceutical formulation using different signal processing techniques of ratio spectra","volume":"157","author":"Ghany","year":"2016","journal-title":"Spectrochim. Acta A Mol. Biomol. Spectrosc."},{"key":"10.1016\/j.jpba.2026.117554_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13065-017-0264-6","article-title":"Rapid simultaneous determination of indacaterol maleate and glycopyrronium bromide in inhaler capsules using a validated stability-indicating monolithic LC method","volume":"11","author":"Zayed","year":"2017","journal-title":"Chem. Cent. J."},{"key":"10.1016\/j.jpba.2026.117554_bib14","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.saa.2018.06.078","article-title":"Validated ion pair chromatographic method for simultaneous determination and in vitro dissolution studies of indacaterol and glycopyrronium from inhaled capsule dosage form","volume":"204","author":"Salem","year":"2018","journal-title":"Spectrochim. Acta A Mol. Biomol. Spectrosc."},{"key":"10.1016\/j.jpba.2026.117554_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.microc.2020.104779","article-title":"Capillary electrophoresis with field-amplified sample stacking for simultaneous determination of indacaterol and glycopyrronium in inhaler capsules: Application to human plasma and urine","volume":"155","author":"Zayed","year":"2020","journal-title":"Microchem. J."},{"key":"10.1016\/j.jpba.2026.117554_bib16","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1007\/s11094-025-03315-1","article-title":"Method development and validation for simultaneous estimation of indacaterol and mometasone using RP-HPLC","volume":"58","author":"Bansode","year":"2025","journal-title":"Pharm. Chem. J."},{"key":"10.1016\/j.jpba.2026.117554_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2023.115553","volume":"234","author":"Youssef","year":"2023","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2026.117554_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.microc.2023.108950","article-title":"Eco-friendly micellar HPLC approach for assessment of two anti-asthmatic breezhalers; Application of central composite design","volume":"192","author":"Bahgat","year":"2023","journal-title":"Microchem. J."},{"key":"10.1016\/j.jpba.2026.117554_bib19","first-page":"676","article-title":"Design of experiment-based green UPLC-DAD method for the simultaneous determination of indacaterol, glycopyrronium and mometasone in their combined dosage form and spiked human plasma","volume":"62","author":"Tarek","year":"2024","journal-title":"J. Chromatogr. Sci."},{"key":"10.1016\/j.jpba.2026.117554_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.microc.2024.111586","article-title":"Sustainable quantification of glycopyrronium, indacaterol, and mometasone along with two genotoxic impurities in a recently approved fixed-dose breezhaler formulations and biological fluids: A machine learning-augmented UV-spectroscopic approach","volume":"206","author":"Abbas","year":"2024","journal-title":"Microchem. J."},{"key":"10.1016\/j.jpba.2026.117554_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.chroma.2024.464696","article-title":"Rapid enantiomeric separation of indacaterol by electrokinetic chromatography","volume":"1717","author":"Salido-Fortuna","year":"2024","journal-title":"J. Chromatogr. A"},{"issue":"6","key":"10.1016\/j.jpba.2026.117554_bib22","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1177\/1469066720971550","article-title":"Identification and characterization of degradation products of indacaterol using liquid chromatography\/mass spectrometry","volume":"26","author":"Yerra","year":"2020","journal-title":"Eur. J. Mass Spectrom."},{"key":"10.1016\/j.jpba.2026.117554_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2020.113145","article-title":"Synthesis and characterization of oxitropium bromide related substances and novel stability indicating HPLC methods","volume":"183","author":"Bellur Atici","year":"2020","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2026.117554_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2023.115325","article-title":"Development and validation of a stability-indicating RP-HPLC method for the determination of fifteen impurities in rivaroxaban","volume":"228","author":"Rao","year":"2023","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2026.117554_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2023.115435","article-title":"HPLC separation, synthesis, isolation and characterization of process related and degradation impurities in larotaxel including method development and validation","volume":"233","author":"Yao","year":"2023","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2026.117554_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2023.115517","article-title":"Structural characterization and in silico toxicity prediction of degradation impurities of roxadustat","volume":"234","author":"Mahajan","year":"2023","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2026.117554_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2023.115568","article-title":"The first RP-UHPLC method for simultaneous quantification of abiraterone acetate, its four degradants, and six specified process impurities and correct identification of all analytes based on molecular weight","volume":"234","author":"Mhaske","year":"2023","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2026.117554_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2023.115845","article-title":"Investigation of aclidinium bromide degradation by stability-indicating HPLC methods, characterization of impurities by NMR, and identification of degradation products by LC-MS","volume":"238","author":"Yazar","year":"2024","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2026.117554_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2024.116117","article-title":"LC-HRMS and NMR studies for the characterization of degradation impurities of ubrogepant along with the in silico approaches for the prediction of degradation and toxicity","volume":"243","author":"Chaganti","year":"2024","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2026.117554_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2025.116757","article-title":"Development and validation of stability-indicating UHPLC-UV-MS tandem methods for lenalidomide assay, related substances, and genotoxic impurity monitoring","volume":"258","author":"A\u011fta\u015f","year":"2025","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2026.117554_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2025.116926","article-title":"Impurity profiling and stability analysis of enzalutamide: identification, genotoxicity assessment, and development of UHPLC methods for critical impurities","volume":"263","author":"Oktar Uzun","year":"2025","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2026.117554_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2024.116085","article-title":"Impurity assessment, development and validation of an RP-HPLC method for the determination of eleven potential impurities of eltrombopag precursor","volume":"243","author":"Demirhan","year":"2024","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2026.117554_bib33","unstructured":"ICH Guideline Q3A (R2), Step 5, Impurities in new drug substances, European Medicines Agency, CPMP\/ICH\/2737\/99, October 2006, \u3008https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-q-3-r2-impurities-new-drug-substances-step-5_en.pdf\u3009."},{"key":"10.1016\/j.jpba.2026.117554_bib34","unstructured":"ICH Q2 (R2) Guideline on validation of analytical procedures, Step 5, European Medicines Agency, EMA\/CHMP\/ICH\/82072\/2006, December 2023, \u3008https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-q2r2-guideline-validation-analytical-procedures-step-5-revision-1_en.pdf\u3009."},{"key":"10.1016\/j.jpba.2026.117554_bib35","unstructured":"ICH Guideline Q1A (R2), Step 5, Stability testing of new drug substances and products, European Medicines Agency, CPMP\/ICH\/2736\/99, August 2003, \u3008https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-q-1-r2-stability-testing-new-drug-substances-and-products-step-5_en.pdf\u3009."},{"key":"10.1016\/j.jpba.2026.117554_bib36","unstructured":"ICH Guideline Q1B, Step 4, Stability testing: Photostability testing of new drug substances and products Q1B, International Conference on Harmonisation, January 1998, \u3008https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-q-1-b-photostability-testing-new-active-substances-and-medicinal-products-step-5_en.pdf\u3009."},{"key":"10.1016\/j.jpba.2026.117554_bib37","unstructured":"ICH M7 (R2) Guideline on assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk, Step 5, European Medicines Agency, EMA\/CHMP\/ICH\/83812\/2013, July 2023, \u3008https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-m7r2-guideline-assessment-and-control-dna-reactive-mutagenic-impurities-pharmaceuticals-limit-potential-carcinogenic-risk-step-5_en.pdf\u3009."},{"key":"10.1016\/j.jpba.2026.117554_bib38","unstructured":"ICH M7 Classification Report, Nexus 2.9.1; Derek Nexus: 6.5.1, Derek KB 2025 1.0; Sarah Nexus: 5.1.0, Sarah mutagenicity model \u2013 2025.1, V1.13; Species: Bacterium, Endpoint: Mutagenicity in vitro."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708526002220?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708526002220?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T17:16:39Z","timestamp":1783185399000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708526002220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":38,"alternative-id":["S0731708526002220"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2026.117554","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comprehensive impurity profiling and stability assessment of indacaterol maleate integrating LC\u2013MS and in silico genotoxicity","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2026.117554","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117554"}}